Skip to content

Startup & venture capital news

VectorY Therapeutics raises EUR 74.5m for ALS gene therapies

New financing supports development of vectorised antibody treatments.

By /

LinkedInX
VectorY Therapeutics: VectorY Therapeutics raises EUR 74.5m for ALS gene therapies

VectorY Therapeutics raised EUR 74.5 million to advance its pipeline for amyotrophic lateral sclerosis and other neurodegenerative diseases. The Amsterdam biotechnology company develops vectorised antibody treatments intended to deliver therapeutic proteins in the nervous system. Invest-NL committed EUR 7 million as part of the financing. The announcement did not assign a conventional Series stage or identify one lead investor, so both are recorded conservatively. The capital will support research, manufacturing and clinical development. The financing and Dutch base were confirmed through the company announcement and Invest-NL.

Keep reading

More Funding

All stories